3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
2
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Cholangiocarcinoma
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Liver Neoplasms
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Acrocephalosyndactylia
1
Interventions
tremelimumab
4
Cystoscopy
3
durvalumab
2
avelumab
2
Paclitaxel
2
Gemcitabine
2
Docetaxel
2
Cisplatin
2
vocimagene amiretrorepvec
1
vinflunine
1
trebananib
1
trastuzumab duocarmazine
1
pegfilgrastim
1
merphos
1
infigratinib
1
erdafitinib
1
efineptakin alfa
1
copanlisib
1
atezolizumab
1
Vinblastine
1
Trastuzumab
1
Taxes
1
TAS-116
1
Specimen Handling
1
Sirolimus
1
Rosiglitazone
1
Ropivacaine
1
Rogaratinib
1
Radiotherapy
1
Polymerase Chain Reaction
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Urinary Bladder Neoplasms
×
infigratinib
×
Clear all
NCT04972253
2022-08-10
(BLASST)-3
Dana-Farber Cancer Institute
Phase 1
Withdrawn